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Abstract
The transition from pregnancy to lactation is a critical event in the
survival of the newborn since all the nutrient requirements of the
infant are provided by milk. While milk contains numerous
components, including proteins, that aid in maintaining the health
of the infant, lactose and milk fat represent the critical energy
providing elements of milk. Much of the research to date on
mammary epithelial differentiation has focused upon expression of
milk protein genes, providing a somewhat distorted view of alveolar
differentiation and secretory activation. While expression of milk
protein genes increases during pregnancy and at secretory
activation, the genes whose expression is more tightly regulated at
this transition are those that regulate lipid biosynthesis. The sterol
regulatory element binding protein (SREBP) family of transcription
factors is recognized as regulating fatty acid and cholesterol
biosynthesis. We propose that SREBP1 is a critical regulator of
secretory activation with regard to lipid biosynthesis, in a manner
that responds to diet, and that the serine/threonine protein kinase
Akt influences this process, resulting in a highly efficient lipid
synthetic organ that is able to support the nutritional needs of the
newborn.
Introduction
Over the past 12 years our understanding of the regulation of
milk protein gene expression has improved dramatically. One
important advance was the discovery of the Janus kinase
(JAK)/signal transducer and activator of transcription (STAT)
pathway; prolactin (PRL)-induced activation of JAK2 and
STAT5 is required to induce expression of most, if not all, milk
protein genes [1,2]. Recent advances suggest that the trans-
cription factor Elf5 and the ubiquitin ligase Socs2
(suppressor of cytokine signaling) are important mediators of
PRL action. Loss of Socs2, which negatively regulates the
PLR receptor (PRLR), or forced expression of the Elf5
transcription factor can restore lactation in mice that fail to
lactate due to the loss of one or both alleles encoding the
PRL receptor [3]. These findings led the investigators to
suggest that Elf5 is encoded by one of the master controller
genes that regulate alveolar differentiation (recently termed
the alveolar switch in a review by Oakes and colleagues [4] in
this series of reviews). Despite these advances, our under-
standing of the molecular changes that underlie alveolar
differentiation and secretory activation (the lactation switch)
is relatively unsophisticated. In this review we identify
changes that are known to occur in the mouse as a means to
identify questions and challenges for the coming decade and
suggest that sterol regulatory element binding protein
(SREBP)-1c and the serine/threonine protein kinase Akt1
play a major role in the lactational switch.
Morphological differentiation of the murine
mammary gland
The morphological changes that occur in the mammary gland
during puberty, pregnancy and lactation are well established
[5]. A rudimentary mammary ductal structure is established in
utero [6] and all subsequent developmental events occur
after birth. Ductal elongation and branching occur primarily
after the onset of puberty under the influence of estrogen,
epidermal growth factor, and insulin like growth factor (IGF)-1
[7,8]. The terminal end bud is the primary proliferative
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structure that directs ductal elongation, which appears to
occur maximally between three to six weeks of age. By ten to
twelve weeks of age the ducts have reached the margins of
the fat pad, the terminal end buds regress to form terminal
ducts, and ductal elongation ceases. In contrast to humans,
in which ten to fifteen branching ducts connect to the nipple,
in the mouse a single primary duct, which can be identified by
its proximity to the nipple and the thick sheath of connective
tissue, serves as a conduit for the passage of milk to the
suckling young. Secondary and tertiary ducts, which contain
a single layer of cuboidal luminal epithelial cells surrounded
by a layer of basal cells, are formed by branching off the
primary duct. Formation of lateral and alveolar buds occurs in
the post-pubertal mammary gland following initiation of the
estrous cycle [9,10]. These lateral buds are often termed side
branches and represent the origin of the alveoli that are the
milk producing cells in the lactating mammary gland [5].
In the post-pubertal phase, alveolar buds develop into
rudimentary alveolar structures consisting of a single layer of
luminal epithelial cells surrounding a circular luminal space. A
layer of flattened myoepithelial cells can be seen to surround
these structures if specific stains, such as rhodamine
phalloidin (an actin stain), are used. During post-pubertal
growth, PRL and progesterone are responsible for alveolar
bud formation [11-13]. Progesterone is thought to act
through the paracrine production of Wnt4 and Rank ligand
(RankL) by progesterone receptor-positive cells; these para-
crine factors in turn stimulate proliferation of progesterone
receptor-negative cells, leading to side branch formation [14].
RankL is thought to stimulate epithelial cell proliferation and
alveolar differentiation through activation of cyclin D1 via a
pathway that may involve NF-κB [15]. Germline deletion of
either RankL or its receptor results in reduced proliferation
and increased apoptosis of alveolar epithelial cells, a process
that could be modified by activation of Akt [15].
Alveolar differentiation, for example, the formation of lobulo-
alveolar structures capable of milk production, occurs during
pregnancy and is also stimulated by PRL [16,17].
Transcription profiling studies indicate that PRL stimulates
transcription of Wnt4 [18], RankL [18], and cyclin D1 via
induction of IGF-2 [19,20]. PRL also induces the expression
of two other transcription factors of note: the ETS
transcription family member Elf5 [3] and SREBP1 [21]. Harris
and colleagues [3] demonstrated that forced expression of
Elf5 in mammary epithelial cells from PRLR knockout mice is
able to restore morphological differentiation and production
of milk proteins. In these experiments it could not be
determined whether Elf5 induced a functional restoration
since the transfected mammary epithelial cells were
transplanted into a recipient host and lactation does not
occur in these mice due to the lack of ductal connections
with the teat. The role of SREBP1 will be discussed below as
it regulates the expression of a number of key lipid
metabolism genes [22].
Histological changes in mammary gland morphology in the
mouse during pregnancy and lactation are shown in Figure 1.
Initial changes observed during pregnancy include an
increase in ductal branching and the formation of alveolar
buds (Figure 1a); this phase of differentiation is characterized
by the largest increase in DNA synthesis and cellular
proliferation during pregnancy [23]. The latter half of
pregnancy is characterized by the expansion of alveolar buds
to form clusters of lobuloalveolar units, followed by the differ-
entiation of these structures into pre-secretory structures. By
day 12 of pregnancy there is a readily apparent increase in
the size of the epithelial compartment compared to the
adipose compartment (Figure 1c), and expansion of the epi-
thelium continues until the epithelial compartment predominates
Figure 1
Histological features of the mammary gland of FVB mice during
pregnancy and lactation. Mammary glands were isolated from FVB
mice on (a,b) day 6 (P6), (c,d) day 12 (P12), and (e,f) day 18 (P18) of
pregnancy, and (g,h) day 2 (L2) and (i,j) day 9 (L9) of lactation, fixed in
neutral-buffered formalin, sectioned and stained with hematoxylin and
eosin. Scale bars in (a, c, e, g and i) represent 100 µm, while those in
(b, d, f, h and j) represent 10 µm.Page 3 of 14
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by late pregnancy (Figure 1e). The luminal space is clearly
evident by late pregnancy, filled with a proteinaceous
substance whose identity is not clear but may represent milk
proteins, glycoproteins such as Muc1, lactoferrin, and
possibily immunoglobulins (Figure 1f). Large lipid droplets are
also present in the cytoplasm of the alveolar epithelial cells
and, to some extent, in the luminal space (Figure 1f). Follow-
ing parturition, the secretory lobuloalveolar structures
become more apparent as the luminal space expands, and
the epithelial cell layer becomes more prominent against the
adipocytes (Figure 1g). The large lipid droplets, which were
present at day 18 of pregnancy, are not present, having been
replaced by small lipid droplets at the apical surface of the
epithelial cells (Figure 1h), and although the luminal space
may contain proteinaceous material when it has not been lost
during fixation and sectioning, it stains much more lightly than
during late pregnancy (Figure 1i versus 1b). By day nine of
lactation in the mouse, the mammary gland is producing
copious amounts of milk. Examination of the histology of the
mammary gland at this stage reveals prominent luminal
structures and ducts; however, few adipocytes are visible at
this time (Figure 1i). This change is thought to reflect
delipidation of adipocytes rather than a decrease in their
number [24].
Perhaps the most obvious histological change marking the
transition from pregnancy to lactation is the change in the
size and cellular distribution of lipid droplets. At mid-
pregnancy, small lipid droplets, referred to as cytoplasmic
lipid droplets (CLDs), can be seen within luminal mammary
epithelial cells. While these are readily apparent in standard
histological sections stained with hematoxylin and eosin, we
have found that they are better appreciated in sections that
are stained with an antibody to adipophilin, which is found at
the periphery of all lipid droplets within the alveolar cells (red
stain in Figure 2) where DAPI (blue stain in Figure 2) has
been used to stain the nuclei, and wheat germ agglutinin
(green stain in Figure 2) to identify the luminal surface of the
Available online http://breast-cancer-research.com/content/9/1/204
Figure 2
The size and location of cytoplasmic lipid droplets (CLDs) changes upon secretory activation. Mammary glands were isolated from FVB mice on
pregnancy (P) days (a) 12, (b) 16, and (c) 18, and (d) day 2 of lactation (L2). Tissues were fixed in neutral-buffered formalin, stained with
anti-adipophilin (ADRP) antibody and Alexa Fluor 594 conjugated secondary antibody to outline the cytoplasmic lipid droplets (appearing in red),
Alexa Fluor 488-conjugated wheat germ agglutinin to outline the luminal surface of the luminal space of the secretory alveoli (appearing in green),
and 4′,6-diamino-2-phenylindole (DAPI) to stain the nuclei of mammary epithelial cells (appearing in blue). Idealized schematic drawings, not meant
to represent the micrographs shown in the top panel, illustrate the positions of the luminal space (labeled LU), nuclei (purple), and CLDs (labeled
red) at pregnancy days (e) 12, (f) 16, and (g) 18, and (h) day 2 of lactation. The scale bars in (a-d) represent 10 µm. Luminal space is indicated by
the letters ‘Lu’, and the white arrowheads indicate CLDs.lobuloalveolar complexes (Figure 2). By the end of pregnancy
the CLDs have increased dramatically in size (Figure 2c,g).
Following parturition, CLDs are smaller and localized to the
apical surface of the alveolar epithelial cells (Figure 2d,h). It is
interesting to note that in many genetically engineered mice
that exhibit lactation failure, large CLDs remain after
parturition and can be observed on the first and sometimes
even the second day of lactation. In particular, we have
characterized lactation failure in transgenic mice that express
activated myr-Akt1 in the mammary gland [25]; prominent
CLDs are apparent following parturition, suggesting that
secretory activation has not occurred. The presence of large
CDLs post-partum is also noted in the following genetically
engineered mice: Src null mice (MM Richert and SM
Anderson, unpublished data); WAP-human protein C [26];
bovine oxytocin transgenic [27]; oxytocin knockout mice [28];
α-lactalbumin knockout mice [29]; butyrophilin knockout mice
[30]; and the xanthine oxidoreductase heterozygous knockout
mice [31].
Functional differentiation of the mammary
gland
Functional differentiation of the murine mammary gland is
divided into four phases: the proliferative phase of early
pregnancy; the secretory differentiation phase, which starts
during mid-pregnancy; secretory activation, which begins at
or around parturition, depending on the timing of the fall of
progesterone; and lactation. While markers for most of these
phases are recognized, the molecules that regulate the
transition between them are not well understood.
As suggested by its name, the proliferative phase is
characterized by the extensive proliferation of mammary
epithelial cells and begins with conception. In vivo labeling of
proliferating cells in the mammary gland with 3H-thymidine
revealed that 25% of the cells were labeled on day five of
pregnancy [23]. Proliferation decreases from this peak in
early pregnancy until the tissue reaches quiescence just
before parturition [23]. If one can use the changes in the
amount of cytokeratin 19 and claudin 7 RNA as a reflection of
the increase in the epithelial cell content of the gland, there
may be up to a thousand-fold increase in the number of
mammary epithelial cells [32,33]. While this increase in
epithelial cell markers could reflect an increase in the number
of epithelial cells, it might also reflect a change in the size of
these cells, or a change in the patterns of genes expressed in
these cells. Despite the massive proliferation that takes place,
the organization of the epithelium is exquisitely maintained.
While the growth factors that regulate the proliferative phase
are not clear, the expression patterns of three paracrine
growth factors expressed in the mammary gland suggest that
they might contribute to this process: RankL, Wnt4, and
amphiregulin. The roles of Wnt4 and RankL have been
discussed above; these paracrine growth factors appear to
be produced by either stromal cells or mammary epithelial
cells. Amphiregulin expression is reduced in PRLR null mice,
suggesting that its expression may be regulated by PRL [18],
and that it may play a role in alveologenesis, as indicated by
other studies [34].
Secretory differentiation, which in some literature is referred
to as lactogenesis stage I, is defined by several biochemical
changes that reflect a change to a pre-lactational state. An
increase in the activity of lipid synthetic enzymes was
reported in the rabbit mammary gland in a seminal paper by
Mellenberger and Bauman [35]. An increase in the expres-
sion of adipophilin protein and RNA were correlated with the
accumulation of CLDs in the alveolar epithelial cells [25,36],
indicating activation of the lipid synthesis function of these
cells. The production of milk appears to be blocked by the
high plasma concentration of progesterone during pregnancy
[37-40]. In fact, it has been suggested that progesterone
downregulates expression of the PRLR [41]. Evidence in
favor of this notion was obtained by Sakai and colleagues
[42], who ovariectomized mice on day 14 of pregnancy,
finding a dramatic increase in expression of the long form of
the PRLR; an increase in expression of β-casein RNA has
also been observed [43]. Ovariectomy on day 17 of
pregnancy results in tight junction closure [44] as measured
by the sucrose permeability of the epithelium.
Secretory activation, defined as the onset of copious
secretion of milk [45], is set in motion by the drop in the level
of serum progesterone around parturition [43,44,46,47].
Unlike humans, in which plasma PRL levels are high through-
out pregnancy, pituitary PRL secretion increases late in
pregnancy in the mouse and rat. At this time PRL appears to
stimulate maximal activation of the PRLR and STAT5, leading
to a further increase in the transcription of milk protein genes
[2,48]; however, unless progesterone action is inhibited, milk
secretion is not initiated [37-40]. It has been long
appreciated that there is a dramatic increase in the amount of
Golgi and endoplasmic reticulum in alveolar epithelial cells at
secretory activation [49], and it is generally assumed that
these changes are required to support the massive synthesis
and secretion of various milk components. While not a
functional definition, the absence of large lipid droplets in
alveolar epithelial cells provides evidence that this secretory
activation has occurred (Figure 2). Both butyrophilin knockout
(Btn-/-) and xanthine oxidoreductase heterozygous (XRO+/-)
mice accumulate large lipid droplets in the cytoplasm of
mammary epithelial cells due to defects in lipid droplet
secretion [30,31].
Lactation is defined as the continuous production of milk by
the dam. In most species there are two phases: a colostral
phase in which the milk contains large amounts of immuno-
globulins and other immune defense proteins [50], and the
mature secretion phase characterized by the production of
large volumes of milk that support the growth of the newborn.
Although the colostral phase has not been well-characterized
in the mouse, preliminary evidence from the Neville laboratory
Breast Cancer Research    Vol 9 No 1 Anderson et al.
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unpublished data). Mouse milk contains about 12% proteins
(the different caseins, α-lactalbumin, whey acidic protein
(WAP), lactoferrin, secretory immunoglobulin A, and others),
30% lipid, and 5% lactose, a disaccharide that is unique to
milk. With the closure of the tight junctions there is no
transfer of sugars from the blood to the milk. Synthesis of
lactose takes place in the Golgi compartment, where the
required synthetic enzymes are located. In both mice and rats,
lactose is not detected in the mammary gland until the day
before parturition [51,52], and thus lactose synthesis may be
considered a marker of secretory activation. Furthermore, mice
with a null mutation of the gene for α-lactalbumin, an essential
co-factor for lactose synthesis, fail to lactate [53].
Milk fat is primarily triacylglycerides, made up of a glycerol
backbone and esterified fatty acids, which are either derived
from the diet, from adipose tissue stores, or synthesized de
novo in the gland. In mice that are maintained on standard
rodent chow, which contains about 8% of its caloric content
as fat, a large proportion of the free fatty acid is synthesized
in the mammary gland from glucose and, probably, amino
acid precursors. To support the synthesis of milk lipids as
well as lactose there must be a significant programming of
the physiology of alveolar epithelial cells to direct metabolic
precursors to the synthesis of these two compounds.
Microarray studies have allowed us to examine temporal
changes in mammary gene expression during secretory
differentiation and activation in some detail [33]. The results
are summarized in Figure 3, which shows mean relative
expression levels for a number of classes of proteins through
pregnancy and lactation to involution. During pregnancy,
adipocyte genes decline about seven-fold, representing
dilution by the growing alveoli, with a two-fold drop at the
onset of lactation as the alveoli expand further. The overall
expression level of milk protein genes increases about five-
fold during pregnancy, with a further three- to four-fold
increase at parturition. However, these mean values hide a
good deal of variation in individual genes within these groups,
as discussed in the next section. The other categories shown
in Figure 3 remain relatively constant during pregnancy, with a
sharp increase (genes for fatty acid and cholesterol
synthesis) or decrease (genes for fatty acid degradation and
the proteasome) at secretory activation. Examination of
numerous mouse models that exhibit lactation failure tends to
suggest that, if secretory activation does not occur properly,
the mammary gland rapidly undergoes involution [54].
Milk protein synthesis and secretion
Figure 4 shows a summary of array data obtained in both the
Neville laboratory [33] and the Gusterson laboratory [55],
with expression levels of the 14 major milk proteins plotted as
a ratio to their expression on day 17 of pregnancy. Changes
in mRNA expression fall into two categories: The first group
of proteins is shown in the inset in Figure 4; and the mRNA
expression of this group increases 3- to 50-fold during preg-
nancy. This category includes most of the caseins,
Westmeade DMBA8 nonmetastatic cDNA1 (WDNM1), milk
fat globule-EGF-factor-8 (MFGM-E8), WAP and adipophilin.
Expression of the mRNA for these proteins is upregulated no
more than two-fold at secretory activation. Most of the
caseins are expressed in early pregnancy at 30% of the level
on day 17 of pregnancy; on the other hand, the expression
levels of WAP and WDNM1 mRNAs appear to be
insignificant in early pregnancy, turning on between P7 and
P12. Despite these differences, expression of most of these
proteins has been shown to be regulated by PRL [37] acting
through phosphorylation of STAT-5 [56-59]. During preg-
nancy in the rodent, when PRL levels are known to be low, it
is likely that differentiated expression levels respond to
placental lactogens [37]. The levels of PRL rise late in
pregnancy; however, as noted above, the effect of PRL is
suppressed by the high serum levels of progesterone
[37-40]. This being the case, synthesis of these proteins, as
opposed to transcription of their genes, must be regulated at
a level upstream of mRNA transcription. Indeed, in very
elegant work in the laboratories of Rhoads and Barash
[60,61], both polyadenylation of β-casein mRNA and amino
acid availability appear to be involved in the translational
regulation of milk protein synthesis. It is tempting to speculate
Available online http://breast-cancer-research.com/content/9/1/204
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Figure 3
Summary of gene expression during pregnancy and lactation by
functional class. Adipocyte specific genes decline throughout
pregnancy and early lactation while milk protein genes as a class
increase over the same time period. The expression of other classes is
stable during pregnancy, possibly representing expression in both the
adipose and epithelial compartment and increases two- to three-fold
(fatty acid and cholesterol synthesis) or decreases about two-fold (fatty
acid and protein degradation) at parturition. Adipocyte genes, red; β-
oxidation genes, navy blue; proteosome genes, teal; milk protein
genes, brown; fatty acid biosynthesis genes, light brown; cholesterol
biosynthetic genes, pink.that, since the expression of Akt1 increases at secretory
activation, Akt could stimulate translation of milk proteins
through its ability to phosphorylate 4E-BP1, a negative
regulator of translation [62]; however, no evidence exists to
support this speculation. Likewise the Akt-dependent
activation of mammalian target of rapamycin (mTOR) could
stimulate translation through S6 kinase and eEF2 [63,64].
The second category includes a heterogeneous group of
proteins whose expression increases up to 20-fold between
day 17 of pregnancy and day 2 of lactation, shown in the
main graph in Figure 4. Many of these proteins, including α-
lactalbumin (lactose synthesis), butyrophilin and xanthine
oxidoreductase (lipid secretion), and parathyroid hormone
related protein (calcium secretion) turn on secretory
processes. In addition, a major milk mucin, MUC1, and one of
the caseins, ∆-casein, are significantly upregulated at this
time. We understand very little about the regulation of most of
these proteins. MUC1, which has been implicated as a
signaling molecule [65], is known to be repressed by the
ErbB2 pathway acting through the Ras, Raf and
phosphatidylonisitol 3′-kinase pathways [66,67]. Parathyroid
hormone related protein secretion has been shown to be
regulated by calcium availability acting through the calcium
sensing receptor [68]. Xanthine oxidase is upregulated in
response to hypoxia in some tissues; however, it is not clear
that its upregulation at secretory activation is related to
changes in the oxidative state. Despite the importance of α-
lactalbumin and butryrophilin to synthesis of lactose and
secretion of lipid, respectively, little work has been done on
the regulation of these genes - a fertile field for investigation.
Diversion of glucose for lactose synthesis
The synthesis of lactose from glucose and UPD-galactose is
unique to mammary alveolar cells. The reaction is catalyzed
by lactose synthase, a combination of β-1,4 galatosyl
transferase and the essential cofactor α-lactalbumin in the
Golgi compartment (Figure 5). α-Lactalbumin is limiting for
lactose synthesis so the very low gene expression during
pregnancy (Figure 4) prevents inappropriate lactose forma-
tion. The Km for glucose in the lactose synthase reaction is in
the millimolar range so it is important that the glucose
concentration in the alveolar cells be higher than usual, and,
indeed, one of the characteristic features of the lactating
mammary alveolar cell is its high cytoplasmic glucose
concentration. Most cells maintain glucose concentrations in
the range 0.1 to 0.4 mM. As first shown in rats [69] and later
in women [70], the concentration of glucose in the milk is
thought to be the same as that of the mammary alveolar cell.
In women, glucose concentration in milk increases from about
0.34 mM to 1.5 mM during secretory activation [71,72] and
decreases in proportion to milk volume during gradual
weaning [70]. Comparison of fluxes of stable isotopes of
glucose between full lactation and weaning suggested
changes in the activity of a glucose transporter in the basal
membrane; however, there was no effect of insulin on any
milk parameters, including glucose concentration under
conditions of a euglycemic clamp [73]. These findings in
humans are consistent with the presence of a non-insulin
dependent glucose transporter in the plasma membrane and,
as described next, subsequent animal work has shown this
transporter to be glucose transporter (GLUT)1 [74-76].
As shown in Figure 5b, mRNA for GLUT1 is upregulated
significantly at parturition in the mouse, with a 280% increase
in its amount. Studies have shown that this finding is
reflected in the level of the protein as well and immuno-
histochemical results suggest localization to both basal and
Golgi membranes. Treatment of lactating rats with bromocrip-
tine to inhibit the production of PRL by the pituitary caused a
37% decrease in the level of GLUT1, while a combination of
bromocriptine plus anti-growth hormone antibody suppres-
sed the levels of GLUT1 by 90% [77]. Thus, GLUT1 is the
major glucose transporter in the basal membrane and its
expression is regulated by PRL at secretory activation when
the demand for glucose for synthesis of lactose is greatly
amplified.
The expression of hexokinase (HK)I was found to be
constitutive in the rat mammary gland [78] whereas HKII was
found to be present only at lactation. We have recently
confirmed this finding at the protein level in the murine
mammary gland (SM Anderson, unpublished data). While the
differential functions of HKI and HKII are not completely
Breast Cancer Research    Vol 9 No 1 Anderson et al.
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Figure 4
Expression patterns of milk protein genes. The main graph shows
genes whose expression increases more than two-fold at parturition.
The inset shows genes with casein-like expression patterns whose
mRNA increases mainly during pregnancy. All data are normalized to
the level of expression at day 17 of pregnancy (P17). ADPH,
adipophilin; MFGM, milk fat globule-EGF-factor; PTHrP, parathyroid
hormone related protein; WAP, whey acidic protein; WDNM1,
Westmeade DMBA8 nonmetastatic cDNA1; xanthine DH, xanthine
oxidoreductase.understood [79], the Km for glucose of HKI is 0.03 mM while
that for HKII is 0.3 mM. The lower affinity of HKII would allow
it to operate in the higher glucose environment of the
lactating mammary cell and might contribute to the higher
cytoplasmic glucose concentration necessary for lactose
synthesis. Furthermore, HKII appears to have two catalytic
sites with differential sensitivity to the feedback inhibition by
glucose-6-PO4, possibly allowing it to function under
conditions inhibitory to HKI [80]. HKI is thought by Wilson
[79] to be best positioned for the catabolic role of intro-
ducing glucose-6-PO4 into the glycolytic chain for generation
of ATP in organs like the brain. The type 2 enzyme is thought
to be better suited for an anabolic role, being present in
insulin sensitive tissues like skeletal muscle and adipose
tissue as well as in the liver and lactating mammary gland
[78]. In the last three tissues, glucose-6-PO4 is directed into
the pentose phosphate shunt to provide NADPH for lipid
synthesis. Thus, the putative switch from HKI as the sole
enzyme for glucose phosphorylation to the presence of both
HKI and HKII may lead to both an increase in free glucose for
lactose synthesis and increased activity of the pentose
phosphate shunt.
Milk lipid synthesis and secretion
The mouse mammary gland is quite a unique lipid
biosynthetic organ: the FVB mouse has about 2 g of
mammary tissue estimated to secrete 5 ml of milk containing
approximately 30% lipid, or 1.5 g of lipid per day. Over the
course of a 20 day period of lactation, therefore, the dam
secretes nearly 30 g of milk lipid, which is equivalent to her
entire body weight! Over 98% of the fat in milk is triglyceride,
which is synthesized by the condensation of fatty acids with
glycerol derived from the plasma as free glycerol or from
glucose through the synthesis of dihydroxyacetone phos-
phate (DHAP) (Figure 6). Fatty acids are either transported
from the plasma or derived from the de novo synthesis of
medium chain fatty acids from glucose in the epithelial cells
[81,82]. Importantly, these functions are regulated both at
secretory activation (Figure 3) and by the availability of
exogenous lipid from either the diet or breakdown of adipose
triglyceride (Figure 6). In the fed state under high fat diet
conditions, dietary lipid is transferred to the mammary alveolar
cell in the form of chylomicrons. The triglyceride in these
particles is broken down by lipoprotein lipase into glycerol
and fatty acids, both of which are taken up into the alveolar
Available online http://breast-cancer-research.com/content/9/1/204
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Figure 5
Regulation of glucose entry and utilization in the lactating mammary alveolar cell. (a) Glucose enters the cell via glucose transporter (GLUT)1, a
non-insulin sensitive transporter. Free glucose enters the Golgi via GLUT1 where it is combined with UDP-galactose, also derived from glucose to
make lactose. Since the Golgi membrane is not permeable to disaccharides, lactose draws water osmotically into the Golgi compartment. Glucose
is also converted to glucose-6-PO4 by hexokinase. The glucose-6-PO4 can be isomerizedby glucose-6-PO4 isomerase to fructose-6-PO4 from
whence it is made into pyruvate or glycerol-3-PO4. Glucose-6-PO4 may also enter the pentose phosphate shunt, a major source of NADPH for lipid
synthesis. Pyruvate enters the mitochondrion where two major products are ATP, which provides energy to synthetic processes in the cell, and
citrate. Citrate has two fates: it serves as the substrate for fatty acid synthesis by conversion to malonyl-CoA and it can be converted to pyruvate
through the malate shunt, which provides additional NADPH. NADPH, glycerol-3-PO4, and pyruvate all contribute to triglyceride (TAG) synthesis.
(b) Profile of GLUT1, citrate synthase, the citrate transporter, ATP citrate lyase, and glucose phosphate isomerase showing upregulation of the first
four and down regulation of the last. (c) Profile of enzymes whose mammary expression is downregulated by a high fat diet. (d) Profile of enzymes
that lead to synthesis of polyunsaturated, long chain fatty acids in the mouse mammary gland. P17, day 17 of pregnancy.cell to be used for triglyceride synthesis. The process is
augmented by synthesis of dihydroxyacetone phosphate, a
precursor of glycerol-3-PO4, and fatty acids from glucose.
During fasting, if adipose stores are replete with fat, fatty
acids are transferred from adipose tissue bound to albumin
and are available for transport into the mammary alveolar cell.
Very low density lipoprotein (VLDL) from the liver also
transports fatty acids to the mammary gland; however, the
quantitative significance of this process is not well
understood. Under conditions of a low fat diet, the type
routinely encountered by lactating mice, at least under
laboratory conditions, glucose becomes a most important
substrate for both glycerol and fatty acid synthesis. In addition,
a massive increase in amino acid transport suggests that
certain amino acids could also enter the fatty acid synthetic
pathway via the citric acid cycle. Milk lipid content data from
cows infused with extra methionine support this notion [83].
The expression of several key enzymes for fatty acid synthesis
is altered at the mRNA level at secretory activation, suppor-
ting the increased formation of fatty acids for triglyceride
synthesis [84]. Notably, these findings are supported by a
secondary analysis of data from a similar time course study by
Stein and colleagues [55]. First, glucose-6-PO4 isomerase is
downregulated (Figure 5b) and the enzymes for substrate
entry into the pentose phosphate shunt are upregulated such
that glucose-6-PO4 is shunted toward NADPH production,
an essential reducing agent required for fatty acid synthesis.
In early biochemical studies the increased activity of the
pentose phosphate shunt at the onset of lactation was found
to be a major contributor to increased lipogenesis at the
onset of lactation [85]. As stated above, the presence of HKII
may contribute to this increase. Second, a special form of
aldolase, aldolase C, is upregulated to facilitate glycerol
formation, similar to the myelinating brain. Expression of this
gene product has been shown to be PRL sensitive [86].
Third, at least a portion of mitochondrial activity is subverted
by the continued high expression of both pyruvate
carboxylase and pyruvate dehydrogenase, leading to the
synthesis of large quantities of citrate, which is then exported
to the cytoplasm by the mitochondrial citrate transporter,
whose expression is also significantly upregulated
(Figure 5b). Fourth, increased expression of ATP citrate lyase
(Figure 5b) facilitates the formation of acetyl CoA, used both
for malonyl CoA synthesis and in the so-called malate shuttle,
which leads to additional production of NADPH. Fifth,
malonyl-CoA is utilized by fatty acid synthase in a sequence
of seven reactions, each requiring two molecules of NADPH
to produce fatty acids [87]. Finally, many of the genes that
determine the nature of the fatty acids in the triglyceride are
upregulated in the mouse mammary gland at secretory
activation, including the sterol CoA dehydrogenase (SCD)
types 1 and 2, the ∆5 desaturase, and elongase (Figure 5c,d)
[84].
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Figure 6
Sources of substrate for milk lipid synthesis. The substrate for triacylglycerol synthesis depends on plasma sources of substrate. In the high fat fed
animal, such as the usual lactating women who consumes up to 40% of her calories as lipid, fatty acids and glycerol for the synthesis of milk
triglycerides (TAGs) originate in the chylomicra and very low density lipoprotein (VLDL) of the liver, whereas only about 10% of TAGs are derived
from glucose. During a fasting state, fatty acids continue to be derived from the plasma, but now are transported to the mammary gland directly
from the adipose tissue bound to albumin or indirectly as VLDL derived from the liver. In the animal fed a low fat diet, such as the laboratory mouse
on the usual chow, a much larger proportion of the fatty acids for TAG synthesis are derived from glucose via the fatty acid synthetic pathways
shown in Figure 4. BM, basement membrane; DHAP, dihydroxyacetone phosphate; ER, endoplasmic reticulum; FA, fatty acid; FABP, fatty acid
binding protein; GLUT, glucose transporter; LPL, lipoprotein lipase.Many of these same genes have been found to be down-
regulated in other tissues in response to high fat diets [88]. In
particular, those genes that responded to a high fat diet in the
mammary gland include citrate synthase, the citrate
transporter, ATP citrate lyase, malic enzyme and SCD 1 and
2; their profiles are shown in Figure 5b,c. As we shall see
below, the transcription factor SREBP1c is an important
regulator of this effect.
A study by Naylor and colleagues [21] employed three
different mouse models that each exhibit failed lactation
(PRLR-/- mice, Galanin-/- mice, and mice treated with a
phosphomemic mutant of PRL (S179D), which inhibits
lactogenesis and lactation), and identified 35 probe sets
whose expression was altered in all three models. Consistent
with our contention that regulation of lipid synthesis is an
important part of secretory activation, a number of lipid
synthesis genes were downregulated in this study, including
ATP citrate lyase, aldolase C, SCD2, and an elongase, Elov5,
suggesting that these genes are very sensitive to the lactation
state of the animals, as might have been predicted from
studies of their activation during the onset of lactation.
Regulation of lipid biosynthesis in the
mammary gland: a central role for SREPB1?
Figure 7 shows the expression of a number of genes known
to be involved in the regulation of lipid synthesis in liver,
adipose tissue and the mammary gland. Two expression
patterns emerge. Several factors, shown by the dotted lines
in Figure 7, are downregulated up to ten-fold or more during
pregnancy, consistent with the pattern of expression of
adipocyte genes shown in Figure 3. These include Akt2,
peroxisome-proliferator-activated receptor-gamma (PPAR-γ),
and liver X receptor-beta (LXR-β), all known to be involved in
regulation of lipid synthesis in adipose tissue. On the other
hand, Akt1, the long form of the PRLR, SREBP1, and a
protein thought to be important in the regulation of fatty acid
synthesis, SPOT 14 [89], are all significantly upregulated
between day 17 of pregnancy and day 2 of lactation. We
have shown that Akt1 is dramatically upregulated at both the
mRNA and protein levels during lactation [25,90] and have
previously described the lactation failure that occurs in
transgenic mice expressing constitutively activated myr-Akt1
in the mammary gland [25]. CLD formation occurs during
early pregnancy in these mice, and they produce milk with an
elevated lipid content (25% to 30% in normal FVB mice
versus 65% to 70% in the transgenic mice by creamatocrit, a
volume/volume method) [25]. Microarray studies comparing
myr-Akt1 transgenic mice to FVB control mice indicate that
expression of several key regulatory fatty acid biosynthetic
enzymes is elevated during pregnancy in these transgenic
mice, including SREBP1, Insig1, and Spot 14 (MC Rudolph,
MC Neville, and SM Anderson, unpublished data).
Real-time PCR measurements confirm the upregulation of
SREBP1 at the transition from pregnancy to lactation and
show that it is the SREBP1c form that is increased [84],
consistent with a role as a regulator of the expression of fatty
acid biosynthetic enzymes [22]. The SREBPs are shuttled by
the SREBP cleavage activating protein (SCAP), which binds
to them at the endoplasmic reticulum and escorts them to the
Golgi apparatus where they are proteolytically cleaved to
generate active transcription factors. The newly generated
fragment of SREBP1 is a member of the basic helix-loop-helix
transcription factor family capable of activating the
transcription of genes for the synthesis of fatty acids, while
SREBP2 activates cholesterol synthesis. SREBP1 is able to
activate its own transcription due to the presence of a sterol
response element in the promoter region of the gene
encoding SREBP1 [91,92]. Insig, an endoplasmic reticulum
resident binding protein for the SREPB1s also has a sterol
response element in its promoter; our finding that it is also
upregulated at secretory activation is additional evidence for
a role for SREBP1 at this time. The promoters for many of the
genes involved in fatty acid biosynthesis contain sterol
response elements in addition to binding sites for nuclear
factor (NF)-Y, upstream factor, specific factor (SP)1 and SP3
[93-98]. The exact roles of these transcription factors are not
understood but it is interesting to note that upstream factor 2
null mice have lowered production of milk that results in
diminished pup weight gain [99]. In these mice the fat
content of the milk is normal but the investigators observed a
reduction in mammary wet weight, epithelial alveolar luminal
area, expression of eukaryotic initiation factors 4E and 4G,
and decreased plasma oxytocin.
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Figure 7
Expression of regulatory genes during secretory differentiation and
activation. Dotted lines show genes that decrease at least ten-fold
during pregnancy, consistent with adipocyte localization. The solid
lines show genes that increase at least two-fold at the onset of
lactation with much smaller changes during pregnancy. These genes
are likely to be important in initiating metabolic changes at secretory
activation. LXR, liver X receptor; P17, day 17 of pregnancy; PPAR,
proliferator-activated receptor; PrlR, prolactin receptor; SREBP, sterol
regulatory element binding protein.A potential role for regulation of SREBP by Akt was revealed
in a study that demonstrated activation of SREBP in cells
expressing activated Akt, resulting in the induction of 24
genes involved in sterol/fatty acid biosynthesis and a
statistically significant increase in saturated fatty acids in
these cells [100]. Akt-dependent induction of fatty acid
synthase, HMG-CoA synthase, and HMG-CoA reductase
required the presence of SREBPs since induction of gene
transcription was blocked by dominant negative mutants of
SREBPs or siRNAs directed against SREBP1a, SREBP1c or
SREBP2 [100]. Furthermore, we have observed that expres-
sion of SREBP is upregulated in the mammary glands of myr-
Akt1 mice (MC Rudolph, MC Neville, and SM Anderson,
unpublished data).
A mechanism by which Akt might regulate activation of
SREBPs has been suggested by the recent work of
Sundqvist and colleagues [101], who demonstrated that
degradation of SREBP is regulated by phosphorylation of
Thr426 and Ser430. These phosphorylation sites serve as
recognition motifs for the binding of the SCFFbw7 ubiquitin
ligase. Binding of SCFFbw7 to SREBP enhances the
ubiquitination and degradation of SREBP [101]; thus, phos-
phorylation of SREBP results in the negative regulation of
SREBP transcriptional activity, and the downregulation of
SREBP-dependent genes. Phosphorylation of Thr426 and
Ser430 is mediated by glycogen synthase kinse (GSK)-3
[101]; the link to Akt is provided by the fact that GSK-3 is the
first known substrate of Akt, and phosphorylation of it by Akt
inhibits its catalytic activity [102]. Therefore, expression of
activated Akt in cells should inhibit the catalytic activity of
GSK-3, leading to a decrease in the phosphorylation of
SREBP by it and a decrease in the resulting degradation of
SREBP; all of these changes should result in the increased
transcription of SREBP-dependent genes, as has been
observed in vitro [100]. Our model proposes that Akt plays a
similar function in the in vivo mammary gland, acting as a
major regulator of fatty acid synthesis at the onset of lactation
by stabilizing SREBPs (Figure 8).
A recent study by Boxer and colleagues [103] indicated that
Akt1-/- mice, but not Akt2-/- mice, exhibit lactation failure. The
absence of Akt1 specifically resulted in a decrease in GLUT1
associated with the baso-lateral surface of mammary
epithelial cells during lactation [103]. Milk protein RNA and
proteins appeared to be the same in both wild-type and
Akt1-/- mice, although there was a marked reduction in total
milk volume. Microarray and quantitative RT-PCR analysis
revealed decreased expression of RNA for stearoyl-CoA
desaturase-2 and stearoyl-CoA desaturase-3 in the mammary
glands of Akt1-/- mice compared to wild-type control mice,
and an increase in diacylglycerol acyltransferase (DGAT)2
expression [103]. No changes in SREBP1a or SREBP1c
expression were detected [103]. These authors note that
ATP citrate lyase is an Akt substrate [104] and observed that
phosphorylation of ATP citrate lyase was decreased in the
Akt1-/- mice. Boxer and colleagues suggest that the
decreased phosphorylation results in a lower catalytic activity
of ATP citrate lyase to hydrolyze citrate to oxaloacetate and
acetyl-CoA; however, it has not been established that
phosphorylation of ATP citrate lyase by Akt has any effect
upon its catalytic activity [104]. We note in Figure 3 that a
decrease in the expression of genes involved in the β-
oxidation of fatty acids occurred at secretory activation, and
Boxer and colleagues noted that this decrease did not occur
in the Akt1-/- mice, suggesting that the failure to suppress
transcription of these genes could result in the increased
degradation of lipid at the same time that mammary epithelial
cells were synthesizing fatty acids for inclusion in the milk
[103]. The results of Boxer and colleagues [103] clearly
provide support for Akt1 playing an important role in
regulating glucose transport and at least some aspects of
lipid biosynthesis in mammary epithelial cells.
Future questions and conclusions
In characterizing mammary gland differentiation and lactation,
most investigators have focused upon the synthesis of milk
proteins, particularly the caseins, since they form a well-
defined set of molecules that can be readily examined at
either the RNA or protein level. Indeed, analysis of expression
of genes such as those encoding caseins and WAP led to
the discovery of the PRLR/JAK2/STAT5 signaling pathway
that regulates their expression. However, expression of these
genes is increased more during pregnancy than at the onset
of lactation. It should be clear from the information presented
in this review that the expression of another set of genes, a
set that includes genes for the enzymes of lipid and
cholesterol synthesis, glucose transport, and synthesis of
lactose, must be under a different type of regulation since
expression is increased only at secretory activation. We
suggest a model by which PRL-induced activation of the
PRLR in the absence of progesterone results in a dramatic
increase in the activation of Akt, which in turn activates a
number of milk synthetic programs, including activation and
stabilization of nuclear SREBP1c (Figure 8), resulting in the
increased expression of lipid biosynthetic enzymes. SREBP1c
may be upregulated by a significant increase in demand for
fatty acids at the onset of lactation, a demand that is not met
by the normal low fat chow (8% of calories as fat) fed to
mice. Thus, many of its downstream genes were down-
regulated in response to a high fat diet (40% of calories as
fat) [84]. A recent study shows a response to lipid feeding in
cows that is consistent with this interpretation [105]. It is not
clear whether PRL directly regulates expression of SREBP1
during secretory activation, or whether other factors such as
IGF-I contribute to this process. Although it does not appear
in the model shown in Figure 8, it will be important to
determine the role of Spot 14 in regulating lipid biosynthesis;
Spot 14 knockout mice exhibit a lactation defect and the milk
of these mice have less triglyceride, apparently resulting from
reduced de novo lipid synthesis [106]. Whether Spot 14 and
SREBP independently regulate different aspects of lipid
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PRL also stimulates the expression of GLUT1, and it may
stimulate the translocation of GLUT1 to various intracellular
compartments that support importation of glucose and the
subsequent synthesis of lactose. In transformed cells, Akt1
appears to stimulate translocation of GLUT1 to the plasma
membrane [107,108]; however, there is currently no indica-
tion of what signaling molecules regulate the translocation of
GLUT1 to the baso-lateral surface of mammary epithelial cells
and to the Golgi at secretory activation. While Akt1 could
control the translocation of GLUT1 to both of these cellular
locations, it is likely that other molecules, for example, IGF-1,
contribute to the differential translocation of GLUT1.
In our model, Stat5 regulates expression of milk protein
genes and Elf5 may do the same. Akt1 does not influence the
expression of the milk protein genes; however, we believe
that it could influence the translation of these genes and
possibly other lactose synthesis genes during lactation
through known substrates for mTOR and S6 kinase that lie
downstream of Akt1 (Figure 8). Such effects might account
for the reduction in total milk synthesis in the Akt null mouse
[103]. A nice experiment here could be to examine the effect
of Akt1 upon the loading of RNAs for milk proteins into
polysomes using the tetracycline-regulated expression of Akt1.
Our model predicts profound defects in lipid biosynthesis in
mammary epithelial cells from Akt1 null mice in the presence of
normal milk protein expression, a prediction that is consistent
with the recent analysis of lactation defects in the Akt1
knockout mouse [103]. While the analysis of these mice has
confirmed a significant role for Akt in milk lipid synthesis, many
questions remain, including how progesterone downregulates
milk synthesis during pregnancy, how diet and Spot 14
contribute to the regulation of lipid biosynthesis, how other
growth factors such as IGF-1 modulate secretory activation,
and how glucocorticoids contribute to the regulation of lipid
synthetic enzymes. Clearly, there is still much work to be done.
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